Our mission is to improve patient care
and save lives.

We never settle for status quo.
PAVmed is a commercial-stage, diversified medical technology company with an imperative to innovate.

ABOUT

our impact

Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit

Lucid Diagnostics Launches First EsoGuard^® Mobile Test Unit

First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida.

our impact

Veris Health Joins CancerX Partnership as Founding Member

Veris Health announced its participation as a founding member of CancerX — a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society, alongside the Office for the National Coordinator for Health Information Technology and Office of the Assistant Secretary for Health.

our impact

First #CheckYourFoodTube precancer testing event

Lucid Diagnostics holds the first #CheckYourFoodTube precancer testing event in partnership with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month.

‍

our Businesses

Delivering health technology innovations.

Our subsidiaries commercialize technologies that offer significant value to healthcare systems, clinicians, and patients—across all sectors of medical technology—device, diagnostics, and digital health.

Diagnostics

Lucid Diagnostics is a medical diagnostics company offering the first and only diagnostics test to detect esophageal precancer and cancer.

View Business

Digital Health

Veris Health is focused on delivering enhanced personalized cancer care through remote patient monitoring using a digital health platform and connected health devices.

View Business

our approach

Pioneering medical technology with a shared-services business model.

Our shared, enabling functions allow us to achieve economies of scale and rapidly deploy resources as needed across our businesses and products.

LEARN MORE

press releases

Read the latest news from PAVmed.

December 23, 2024

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

View Press Release

December 19, 2024

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

View Press Release

December 11, 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

View Press Release

investor relations

Innovation within reach.

Investing in PAVmed is investing in innovation that has the potential to impact and even transform healthcare. Stay informed about the latest news and updates from our team.

INVESTORS